Substituted tricyclic compounds as FGFR inhibitors
US-12534463-B2 · Jan 27, 2026 · US
This page is not indexed by search engines while we improve data quality.
Lu Liang patents
Lu Liang is listed as an inventor on 102 patents in our database. Major assignees and classification codes are summarized below.
| Metric | Value |
|---|---|
| Inventor | Lu Liang |
| Total patents | 102 |
| First publication | Jan 14, 2016 |
| Latest publication | Jan 27, 2026 |
Notable patents
Publications ranked by popularity score, then publication date.
CDK inhibitors and their use as pharmaceuticals
US-12486277-B2 · Dec 2, 2025 · US
Immunomodulator compounds and methods of use
US-2025325660-A1 · Oct 23, 2025 · US
BRM targeting compounds and associated methods of use
US-12448389-B2 · Oct 21, 2025 · US
Crystalline forms of a cdk9 inhibitor and uses thereof
US-2025011298-A1 · Jan 9, 2025 · US
Machine learning model with depth processing units
US-2025005339-A1 · Jan 2, 2025 · US
BRM Targeting Compounds And Associated Methods Of Use
US-2024336612-A1 · Oct 10, 2024 · US
Machine learning model with depth processing units
US-12086704-B2 · Sep 10, 2024 · US
Substituted tricyclic compounds as fgfr inhibitors
US-2024246974-A1 · Jul 25, 2024 · US
BRM Targeting Compounds and Associated Methods of Use
US-2024190886-A1 · Jun 13, 2024 · US
Recent patents
Latest publications not already listed above.
Brm targeting compounds and associated methods of use
US-2024018158-A1 · Jan 18, 2024 · US
Substituted tricyclic compounds as FGFR inhibitors
US-11840534-B2 · Dec 12, 2023 · US
BRM Targeting Compounds And Associated Methods Of Use
US-2023365576-A1 · Nov 16, 2023 · US
Heterocycle CDK Inhibitors And Their Use Thereof
US-2023265083-A1 · Aug 24, 2023 · US
CDK Inhibitors And Their Use As Pharmaceuticals
US-2023242543-A1 · Aug 3, 2023 · US
Heterocyclic compounds as immunomodulators
US-2023226062-A1 · Jul 20, 2023 · US
BRM targeting compounds and associated methods of use
US-11702423-B2 · Jul 18, 2023 · US
Heterocyclic compounds as immunomodulators
US-11673883-B2 · Jun 13, 2023 · US
CDK inhibitors and their use as pharmaceuticals
US-11673893-B2 · Jun 13, 2023 · US
Bicyclic heterocycles as FGFR4 inhibitors
US-11667635-B2 · Jun 6, 2023 · US
Pre-training with alignments for recurrent neural network transducer based end-to-end speech recognition
US-11657799-B2 · May 23, 2023 · US
Sequence-to-sequence speech recognition with latency threshold
US-2023154467-A1 · May 18, 2023 · US
CDK Inhibitors And Their Use As Pharmaceuticals
US-2023144528-A1 · May 11, 2023 · US
Layer trajectory long short-term memory with future context
US-11631399-B2 · Apr 18, 2023 · US
BRM Targeting Compounds And Associated Methods Of Use
US-2023083376-A1 · Mar 16, 2023 · US
Sequence-to-sequence speech recognition with latency threshold
US-11562745-B2 · Jan 24, 2023 · US
Bicyclic heterocycles as FGFR inhibitors
US-11530214-B2 · Dec 20, 2022 · US
Internal language model for E2E models
US-11527238-B2 · Dec 13, 2022 · US
CDK Inhibitors And Their Use As Pharmaceuticals
US-2022324830-A1 · Oct 13, 2022 · US
Heterocyclic compounds as immunomodulators
US-2022194931-A1 · Jun 23, 2022 · US
Major assignees
Companies most often associated with this inventor's publications.
| Assignee | Patents |
|---|---|
| Incyte Corp | 69 |
| Incyte Holdings Corp | 21 |
| Prelude Therapeutics Inc | 16 |
| Microsoft Technology Licensing Llc | 15 |
| Incyte Corp | 2 |
Top CPC classifications
Most common classification codes across this inventor's patents.
| CPC | Patents |
|---|---|
| A61P35/00 | 81 |
| C07D471/04 | 63 |
| A61K31/519 | 39 |
| A61K31/4375 | 35 |
| C07D487/04 | 34 |